BPC-157

Overview

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a chain of 15 amino acids — whose sequence is derived from a protective protein found in human gastric juice. It has become one of the most discussed peptides in the research and athletic communities for its reported effects on tissue repair, tendon and ligament healing, and gut protection.

Before anything else, the essential context: the BPC-157 evidence base is almost entirely preclinical. The promising results below come from rodent and cell-culture studies, predominantly from a single research group (Sikiric and colleagues in Zagreb), with important mechanistic contributions from Pang's group in Taiwan. There are no completed, published human clinical efficacy trials of systemic BPC-157, and a 2025 independent review (Józwiak et al.) explicitly states that "there are no completed clinical studies describing its efficacy in humans."

Mechanism of Action

Animal and in-vitro studies suggest BPC-157 acts through several converging pathways:

• Nitric oxide (NO) system modulation — BPC-157 interacts with the NO pathway, central to blood-vessel function and tissue-repair signaling. This is one of the most consistently described mechanisms (Sikiric et al.).
• Angiogenesis via VEGFR2 — Hsieh et al. showed BPC-157's pro-angiogenic (new blood vessel) effects are associated with activation and upregulation of the VEGFR2–Akt–eNOS pathway, and later work tied it to a Src–Caveolin-1–eNOS axis governing vascular tone.
• Growth factor / tendon fibroblast signaling — promotes tendon fibroblast outgrowth, survival, and migration (FAK–paxillin pathway), supporting connective-tissue repair.
• Gut–brain axis — modulates signaling between the gut and central nervous system, which the Sikiric group has linked to its broad "organoprotective" effects.

Common Research Areas

BPC-157's preclinical literature falls into two main buckets:

Musculoskeletal healing. Rodent studies report accelerated healing of:

• Tendons — including transected Achilles tendon models (Staresinic et al., 2003) and tendon-to-bone healing that resisted corticosteroid-induced impairment (Krivic et al., 2006)
• Ligaments and muscle — crush and transection injury models
• Protocols in these studies typically involve injection near the injury.

Gastrointestinal protection. This is the peptide's origin story — derived from a gastric protein — and the animal data cover protection against:

• NSAID-induced gut damage
• Ethanol- and stress-induced ulcers
• Inflammatory bowel models

The Sikiric group frames these effects within a broader "cytoprotection / adaptive cytoprotection" theory of organ protection.

Protocol Notes

Most preclinical protocols use doses around 1–10 mcg/kg in rodents. Community human protocols — which are extrapolations, not validated regimens — typically range from 200–500 mcg per injection, once or twice daily, for 4–12 weeks. BPC-157 is frequently stacked with TB-500 for soft-tissue injuries, on the theory that their mechanisms are complementary (see the BPC-157 + TB-500 stack profile).

It is worth stressing: the leap from "rodent dose scaled by body weight" to "human protocol" is an assumption, not an established translation.

The Evidence Gap — and Legal/Anti-Doping Status

This section deserves the same weight as the benefits above:

• No completed human efficacy trials. Despite years of community use, BPC-157 has not been validated in controlled human studies. The animal literature, while substantial, is also heavily concentrated in one research group — independent replication is comparatively limited.
• Unapproved drug. The U.S. Department of Defense's Operation Supplement Safety and other regulators classify BPC-157 as an unapproved drug, frequently found illegally in "wellness" products.
• WADA-prohibited. BPC-157 is on the World Anti-Doping Agency Prohibited List under category S0 (non-approved substances) — prohibited at all times, with no therapeutic-use exemption. Athletes subject to drug testing should treat it as banned. Anti-doping authorities note it "has not been extensively studied in humans" and that no safe dose is established.
• Safety unknown. Because there are no controlled human trials, the long-term human safety profile — including any effects on tumor angiogenesis given its pro-angiogenic mechanism — is genuinely unknown.

Bottom Line

BPC-157 has a large, internally consistent preclinical body of evidence pointing to real tissue-repair and gastroprotective effects in animals, with plausible mechanisms (NO system, VEGFR2-driven angiogenesis). What it does not have is human clinical validation, regulatory approval, or an established safety profile — and it is banned in sport. It is best understood as a scientifically interesting but unproven and legally restricted research compound.